3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
7
Phase 3
4
Phase 1/2
4
Phase 2
1
Status
Completed
36
Unknown
7
Recruiting
7
Active not recruiting
7
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
413
Carcinoma, Non-Small-Cell Lung
286
Prostatic Neoplasms
208
Neoplasms
204
Neoplasm Metastasis
180
Melanoma
164
Multiple Myeloma
158
Colorectal Neoplasms
158
Leukemia, Myeloid, Acute
143
Lung Neoplasms
132
Leukemia
126
Lymphoma
118
Pancreatic Neoplasms
117
Recurrence
111
Ovarian Neoplasms
111
Leukemia, Lymphocytic, Chronic, B-Cell
110
Lymphoma, Non-Hodgkin
105
Carcinoma, Renal Cell
104
Brain Neoplasms
90
Myelodysplastic Syndromes
88
Precursor Cell Lymphoblastic Leukemia-Lymphoma
86
Glioblastoma
85
Lymphoma, Large B-Cell, Diffuse
80
Lymphoma, Follicular
79
Carcinoma, Hepatocellular
79
Head and Neck Neoplasms
77
Squamous Cell Carcinoma of Head and Neck
76
Urinary Bladder Neoplasms
66
Stomach Neoplasms
61
Hodgkin Disease
60
Interventions
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Terminated
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Clear all
NCT04152863
2024-08-06
V937-011
Merck Sharp & Dohme LLC
Phase 2
Terminated
85 enrolled
19 charts